Epidemiological Study On Metabolic Syndrome In Community Population Of Jiangsu Province

Objective To investigate the prevalence and epidemic featuresof metabolic syndrome (MS) and the relationship between MS andthyroid stimulating hormone (TSH) in Jiangsu Province. Methods 6758residents from 6 districts of Jiangsu Province, who had lived for at leastfive years and aged over 20, were enrolled in our survey. Fasting plasmaglucose(FBG), triglycerides(TG), high density lipoprotein-C (HDL-C)were measured. Results (1)The crude prevalences of MS were 21.2%,15.5%, 24.6% in total population, male and female, respectively, whilethe standardized rates were 15.9%, 13.1%, 17.9%, accordingly. Femaleand aged people were the populations at high risk of MS. The prevalencesof hypertension(≥130/85mmHg), hypertriglyceridemia, abnormal fastingplasma glucose, low-HDL-C were 87.4%, 59.0%, 44.0%, 67.2%,respectively among MS individuals, of which 54% had only 2 metabolicabnormalities, 34.4% were abnormal with 3 metabolic parameters and11.6% were involved all the four metabolic components. (2)Multiplelogistic regression analysis showed that the risk factors of MS werefemale, age and family history for MS while smoking had a negativecorrelation with MS. (3)The prevalences of MS were 15.0%, 21.2% and25.4% in the low, normal and high TSH groups. The number of abnormalmetabolic components in high-TSH group was more than low and normalTSH groups. The TSH level in MS individuals was higher than that innon-MS subjects. Conclusions (1)There are high prevalences of MS andits related diseases in Jiangsu Province. (2)Aged and female people are athigher risk. Hypertension is the most frequent metabolic abnormalityamong MS individuals. Most MS individuals have only 2 abnormal metabolic components. (3)Female, age and MS family history are riskfactors of MS, while smoking has negative association with MS. (4)HighTSH concentration increases the risk of MS, more attention should bepaid to the metabolic features such as high blood pressure, hyperglycemiaand dyslipidemia in order to decrease the risk of cardiovascular disease inthe patients with thyroid dysfunction.